Illumina Inc
F:ILU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.29
135.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Illumina Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Illumina Inc
NASDAQ:ILMN
|
20.6B USD |
20%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
14%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
162.7B USD |
19%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.9B CHF |
15%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.8B USD |
21%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
38.5B USD |
14%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
259.2B CNY |
30%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
37%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.7B USD |
28%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.3B EUR |
17%
|
Illumina Inc
Glance View
In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Illumina Inc's most recent financial statements, the company has Operating Margin of 20.4%.